• Skip to primary navigation
  • Skip to main content
  • Skip to primary sidebar
  • Skip to footer
  • Advertise
  • Subscribe

MassDevice

The Medical Device Business Journal — Medical Device News & Articles | MassDevice

  • Latest News
  • Technologies
    • Artificial Intelligence (AI)
    • Cardiovascular
    • Orthopedics
    • Neurological
    • Diabetes
    • Surgical Robotics
  • Business & Finance
    • Wall Street Beat
    • Earnings Reports
    • Funding Roundup
    • Mergers & Acquisitions
    • Initial Public Offering (IPO)
    • Legal News
    • Personnel Moves
    • Medtech 100 Stock Index
  • Regulatory & Compliance
    • Food & Drug Administration (FDA)
    • Recalls
    • 510(k)
    • Pre-Market Approval (PMA)
    • MDSAP
    • Clinical Trials
  • Special Content
    • Special Reports
    • In-Depth Coverage
    • DeviceTalks
  • Podcasts
    • MassDevice Fast Five
    • DeviceTalks Weekly
    • OEM Talks
      • AbbottTalks
      • Boston ScientificTalks
      • DeviceTalks AI
      • IntuitiveTalks
      • MedtechWOMEN Talks
      • MedtronicTalks
      • Neuro Innovation Talks
      • Ortho Innovation Talks
      • Structural Heart Talks
      • StrykerTalks
  • Resources
    • About MassDevice
    • DeviceTalks
    • Newsletter Signup
    • Leadership in Medtech
    • Manufacturers & Suppliers Search
    • MedTech100 Index
    • Videos
    • Webinars
    • Whitepapers
    • Voices
Home » Acute decompensated HF treatment device dev WhiteSwell raises $30m in Series B

Acute decompensated HF treatment device dev WhiteSwell raises $30m in Series B

December 13, 2018 By Fink Densford

WhiteSwell

Early stage device developer WhiteSwell said this week it closed a $30 million Series B round of financing to help support continued development and a pivotal study of the company’s technology intended to treat acute decompensated heart failure.

The round was led by RA Capital Management and an InCube Ventures syndicate and joined by other investors, the Galway, Ireland-based company said.

“WhiteSwell’s mission is aligned with our goal of helping to advance more cost-effective and impactful healthcare outcomes. We are excited about the game-changing potential of WhiteSwell’s technology to benefit patients with ADHF and reduce costs,” RA Capital managing director Dr. Andrew Levin said in a press release.

“We’re looking forward to working with WhiteSwell’s experienced leadership team to deliver a compelling new therapy for ADHF, and we see the potential for it to become a blockbuster medtech product. The WhiteSwell approach is disruptive therapy in an area that has experienced relatively little innovation in the past few decades,” InCube Ventures co-founder & managing director Andrew Farquharson said in a prepared statement.

In addition to the funding, WhiteSwell said that former Neuravi CEO and CFO Eamon Brady and Seán Mac Réamoinn have taken up the same roles with WhiteSwell, joining founder Yaacov Nitzan who is acting as chief technology officer.

“WhiteSwell was founded on insights that arose from our team’s research on the complex fluid dynamics of heart failure patients, leading to the company’s innovative leap in treatment strategy. This financing is an important milestone that will enable us to tackle an enormous clinical problem that affects millions of families,” CEO Brady said in a prepared release.

WhiteSwell said it is developing a technology platform focused on removing excess fluid in the interstitial system to treat acute decompensated heart failure. The system is intended to enhance the natural fluid removal process of the lymphatic system, the company said, as there is currently no effective treatment designed to directly remove excess fluid from the lung and other interstitial tissues.

“I am excited about the potential for WhiteSwell’s therapy to accomplish complete decongestion with preservation of renal function, which is considered the holy grail of ADHF treatment. I was immediately intrigued by WhiteSwell’s ingenuity in targeting the lymphatic system, which plays a major role in fluid management, moving interstitial fluid into the vascular system,” Dr. William Abraham of Ohio State University said in prepared remarks.

Filed Under: Business/Financial News, Cardiovascular Tagged With: whiteswell

More recent news

  • NICE recommends Boston Scientific Farapulse pulsed field ablation tech
  • SS Innovations completes first robotic telesurgery for weight loss
  • Johnson & Johnson MedTech adds new CMO for its Electrophysiology business
  • Abbott earns Medicare win for TriClip TEER system
  • Judge says Johnson & Johnson Ethicon owes $76.6M to ChemImage after failed partnership

Primary Sidebar

“md
EXPAND YOUR KNOWLEDGE AND STAY CONNECTED
Get the latest med device regulatory, business and technology news.

DeviceTalks Weekly

See More >

MEDTECH 100 Stock INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.
MDO ad

Footer

MASSDEVICE MEDICAL NETWORK

DeviceTalks
Drug Delivery Business News
Medical Design & Outsourcing
Medical Tubing + Extrusion
Drug Discovery & Development
Pharmaceutical Processing World
MedTech 100 Index
R&D World
Medical Design Sourcing

DeviceTalks Webinars, Podcasts, & Discussions

Attend our Monthly Webinars
Listen to our Weekly Podcasts
Join our DeviceTalks Tuesdays Discussion

MASSDEVICE

Subscribe to MassDevice E-Newsletter
Advertise with us
About
Contact us

Copyright © 2025 · WTWH Media LLC and its licensors. All rights reserved.
The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media.

Privacy Policy